EUCTR2009-015926-13-SE进行中（未招募）1 期
Treatment of Huntington´s disease with OSU 6162 - a pilot study
Sahlgrenska University Hospital0 个研究点目标入组 24 人开始时间: 2009年12月4日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects who have Huntington´s disease diagnosed in a clinical investigation and this has been confirmed in a molecular genetic test showing a CAG repeat length in the range of 39 - 50 repeats.
- •2. In the total functional capacity scale (TFC) the patients will have between 3 and 13 points indicating that the disease has not reached the two most severe stages. TFC consists of estimations on 5 variables; engagement in occupation, capacity to handle financial affairs, capacity to manage domestic responsibilities, capacity to perform activities of daily living, and in which setting the care of the patient can be provided. Each item can be given 0 to 2 or 3 points according to the importance of the item. Zero points are given when the patient has no or very poor function on a specific item. The sum of all items gives an estimation of the functional capacity of the patient. TFC is the best measurement available to evaluate the progress of all aspects of the diseases (motor, behavioral and cognitive).
- •3. Signed informed consent by patients.
- •4. If the general cognitive function of the patient is considered to be mildly impaired an informed consent will also be signed by a close relative living together with the patie
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Significant co-morbidity and alcohol or drug abuse.
- •2. Pregnant women.
- •3. Women of childbearing age not on contraceptives.
- •4. Patients with a disease so severe that a legal representative is necessary.
- •5. Sick sinus syndrome; resting heart rate below 50 beats per minute; congestive heart failure classified as functional Class III or IV by the New York Heart Association; myocardial infarction within six months of randomization; a prolonged QTc interval at screen or pretreatment (defined as a QTc interval of> 450 msec for males or> 470 msec for females); atrio-ventricular conduction block; other clinically significant heart conditions which would negatively impact on the patient completing the study.
- •6. Clinically significant liver and/or an elevation in either total bilirubin, alkaline phosphatase, LDH, SGOT above the laboratory reference. Clinically significant renal disease and/or an elevation in serum creatinine above the laboratory reference.
- •7. Presence of active neoplastic disease.
- •8. Patients who have had electroconvulsive therapy within 90 days.
- •9. Patients with any surgical or medical condition which, in the judgment of the clinical investigator, might interfere with the absorption, distribution, metabolism or excretion of the drug.
- •10. Patients who are using drugs capable of inducing hepatic enzyme metabolism (e.g., barbiturates, rifampicin, carbamazepine, phenytoin, primidone) within the previous
- •4 weeks (or 5 half lives of inducing agent, whichever is longer) before the enrollment in this study.
- •11. Patients with a medical history of seizures.
- •12. Unstable therapies are not allowed but stable therapies are allowed. A stable therapy is defined as having started at least 4 weeks before the study and continued to be unchanged during the study period. Examples of stable therapies on neuroleptics are: haloperidol or risperidon (highest allowed dose 3 mg/daily); antidepressant therapy such as citalopram (highest allowed dose 40 mg/daily), mirtazapin (higest allowed dose 45 mg daily) or sertraline (higest allowed dose 100 mg/daily). Other stable therapies with hypnotics and anxiolytics are also allowed if they are given at doses recommend by the manufactures. Analgetics such as NSAID, acetyl salicylic acid and paracetamol are permitted.
- •13. Use of acute or chronic medications for other medical conditions are allowed based on clinical judgment. Occasional use of over-the-counter (OTC) medications is allowed at the investigator's discretion. All concomitant medications, whether OTC or prescription, are required to be noted on the Concomitant Medication from.
- •14. Tetrabenazine is not permitted during the study and the wash out period before the study is 4 weeks.
- •15. Suicidal patients according to the clinical estimation or more than 2 points on item 9 of the Beck Depression Inventroy (BDI) scale are excluded.
- •16. Abnormal laboratory parameters such as: Hemoglobine, white blood cells count, electrolytes, TSH, T4, B12, folic acid. All levels above the laboratory references level are considered abnormal.
研究者
相似试验
尚未招募
不适用
Repetitive Transcranial Magnetic Stimulation in the treatment of Huntington’s ChoreaHuntington's diseaseNeurological - Neurodegenerative diseasesHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersACTRN12612001173886orth Metropolitan Area Health Service60
Unknown
不适用
Non-invasive Brain Stimulation in Huntington's DiseaseHuntington DiseaseNCT04429230Western University, Canada15
Unknown
1 期
Far Infrared Irradiation for Managing, Control and Treatment of Huntington's Disease (HD)Huntington DiseaseNCT00675077GAAD Medical Research Institute Inc.5
已完成
不适用
Gene Therapy Development and Validation for Huntington's Disease Fibro TG-HDHuntington DiseaseNCT06444217University Hospital, Angers20
已完成
2 期
Effect of PBT2 in Patients With Early to Mid Stage Huntington DiseaseHuntington DiseaseNCT01590888Prana Biotechnology Limited109